Sign in
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Prognostic Value of Subretinal Hyperreflective Material
Russell Pokroy, MD
Updates from the Field
2017
COVID-19 Mortality and Public Mask Usage- Dr. Christopher Leffler
Keyvan Koushan, MD, FRCSC
Member Podcasts
2020
Category: Pharmacology